Evaluation of Tc-99m-labeled photosan-3, a hematoporphyrin derivative, as a potential radiopharmaceutical for tumor scintigraphy

Citation
Ak. Babbar et al., Evaluation of Tc-99m-labeled photosan-3, a hematoporphyrin derivative, as a potential radiopharmaceutical for tumor scintigraphy, NUCL MED BI, 27(6), 2000, pp. 587-592
Citations number
22
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
NUCLEAR MEDICINE AND BIOLOGY
ISSN journal
09698051 → ACNP
Volume
27
Issue
6
Year of publication
2000
Pages
587 - 592
Database
ISI
SICI code
0969-8051(200008)27:6<587:EOTPAH>2.0.ZU;2-3
Abstract
A quick and reproducible method for radiolabeling of Photosan-3(R), a photo sensitizer used worldwide for photodynamic therapy (PDT) of cancer, with ra dioisotope of technetium (Tc-99m) was developed. The radiotracer was evalua ted for radiochemical purity, stability, and finally tissue distribution in a murine tumor model. The Tc-99m-Photosan-3 prepared by using Tc-99m-perte chnetate in place of reduced Tc-99m demonstrated better labeling efficiency (>90%) and reproducibility. The procedure also minimized the radiation exp osure to the radiochemist as handling time was considerably reduced. Due to the commercial availability of Photosan-3(R), the risk of batch-to-batch v ariation in the in Situ synthesis of hematoporphyrin derivative, which is a complex mixture of at least five compounds, was also significantly reduced . The biodistribution studies and tumor scintigraphy confirmed that Tc-99m- labeled Photosan-3(R) was preferentially taken up by the neoplastic tissue in a manner similar to the parent compound. In addition to applications in tumor imaging, Tc-99m-Photosan-3 could also be used for estimating tumor up take of Photosan-3(R) as may be required for individualization of clinical protocols of PDT, NUCL MED BIOL 27;6:587-592, 2000. (C) 2000 Elsevier Scien ce Inc. All rights reserved.